Why AZN rose on Oct 22
Up 2% on Oct 22.
- Our sources do not explain the move yet.
- The S&P 500 fell 1.2% that day.
AZN's Quality Score fell 3 points on Tue, Nov 10, to 10.
Follow AZN's trial news. Pro members can get an alert when AstraZeneca files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 2% on Oct 22.
| The company | Profit up 45% to $10.2B |
| Latest filing | 20-F, Feb 24 |
AstraZeneca seeks FDA approval of HUTCHMED lung cancer drug
AZN closed −1.2% that day.
Expected to report Thu Nov 12, before the open
An officer, Mani Sharma, bought 20 shares on Aug 8. 1 more insider trade this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Averagefor quality, not price, 4 of 14 chart checks firingWhat the Quality Score means
AZN is #21 of 90 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 21 |
Expected to report Thu Nov 12, before the open (in 2 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Feb 10, 2026 | +3.2% | +2.9% | +11.4% |
| Nov 6, 2025 | +3.9% | +3.2% | +8.1% |
Sales grew every year from 2018 to 2025, to $59B. It made a profit in each of the eight years.
RSI 65.4, MACD above signal, above both averages. Not scored.
One insider sold $2.2M across 1 filing in the last 6 months. No open-market buys on record. The newest:
2 trades disclosed in the last six months. The newest:
Officers and directors with a Form 4 in the last 12 months.
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
AZN scores 10 today, which Breakaway calls Average. It is #21 of 90 in Pharma by Quality Score, with 4 of 14 chart checks firing. Up 2% on Oct 22. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
AZN scores 10 today, which Breakaway calls Average (6 to 10). That is #21 of 90 in Pharma by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind AZN's 10.
One insider sold $2.2M across 1 filing in the last 6 months. No open-market buys on record. The newest is Mani Sharma, Insider, who sold $2.2M on May 20.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free for 24 hours. No account. No card. Then keep going with a free account.